iRadimed (NASDAQ:IRMD) CEO Sells 5,000 Shares

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $96.73, for a total transaction of $483,650.00. Following the sale, the chief executive officer owned 2,287,500 shares in the company, valued at $221,269,875. This trade represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

iRadimed Price Performance

Shares of iRadimed stock traded down $0.06 on Monday, hitting $97.13. The company had a trading volume of 86,654 shares, compared to its average volume of 52,845. The stock has a 50-day moving average of $86.38 and a 200-day moving average of $73.05. iRadimed Corporation has a twelve month low of $47.48 and a twelve month high of $98.44. The firm has a market capitalization of $1.24 billion, a P/E ratio of 58.87 and a beta of 1.06.

iRadimed (NASDAQ:IRMD) last posted its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating the consensus estimate of $0.43 by $0.04. The business had revenue of $21.20 million for the quarter, compared to analysts’ expectations of $20.50 million. iRadimed had a net margin of 26.31% and a return on equity of 22.93%. iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. Equities analysts predict that iRadimed Corporation will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The firm also recently declared a special dividend, which will be paid on Tuesday, December 30th. Stockholders of record on Wednesday, December 17th will be paid a dividend of $0.50 per share. The ex-dividend date of this dividend is Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is currently 41.21%.

Institutional Trading of iRadimed

Hedge funds and other institutional investors have recently bought and sold shares of the business. CWM LLC raised its position in shares of iRadimed by 62.2% in the third quarter. CWM LLC now owns 550 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 211 shares in the last quarter. Quarry LP bought a new position in iRadimed during the 3rd quarter worth $40,000. Tower Research Capital LLC TRC raised its holdings in iRadimed by 191.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares in the last quarter. State of Alaska Department of Revenue bought a new stake in shares of iRadimed during the 3rd quarter valued at $47,000. Finally, Spire Wealth Management acquired a new stake in shares of iRadimed during the 2nd quarter worth $60,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on IRMD shares. Lake Street Capital restated a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research note on Monday, November 3rd. Roth Capital set a $90.00 price target on iRadimed in a research report on Friday, October 31st. Weiss Ratings reiterated a “buy (b-)” rating on shares of iRadimed in a research note on Tuesday, December 16th. Wall Street Zen downgraded shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Finally, Zacks Research raised shares of iRadimed to a “hold” rating in a research report on Tuesday, November 4th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $87.33.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.